Glow-in-the-Dark dye could help surgeons spot hidden breast cancer

NCT ID NCT05900986

Completed Diagnosis Sponsor: Integro Theranostics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new imaging dye called LS301-IT in 22 women with early-stage breast cancer (DCIS or stage I-II) who were having a partial mastectomy. The dye is injected into a vein before surgery to make cancer cells glow, helping surgeons see and remove them more accurately. The main goals were to check safety and how well the dye works to spot cancer during the operation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast ductal adenocarcinoma breast neoplasm ductal breast carcinoma in situ invasive breast carcinoma invasive ductal breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DCIS INVASIVE DUCT CARCINOMA OF BREAST

Contacts and locations

Locations

Integro Theranostics Clinical Research Site #8

Winston-Salem, North Carolina, 27103, United States
Integro Theranostics Research Site #10

Cleveland, Ohio, 44195, United States
Integro Theranostics Research Site #12

Washington D.C., District of Columbia, 20059, United States
Integro Theranostics Research Site #2

Scottsdale, Arizona, 85260, United States
Integro Theranostics Research Site #3

Dallas, Texas, 75290, United States
Integro Theranostics Research Site #5

Philadelphia, Pennsylvania, 19107, United States
Integro Theranostics Research Site #6

The Bronx, New York, 10461, United States
Integro Theranostics Research Site #9

Weston, Florida, 33331, United States
Integro Theronostics Research Site #1

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.